SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mak, A
Right arrow Articles by Mok, C C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mak, A
Right arrow Articles by Mok, C C
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus

A Mak

Department of Medicine, Tuen Mun Hospital, New Territories, Hong Kong, anselmmak{at}netvigator.com

C C Mok

Department of Medicine, Tuen Mun Hospital, New Territories, Hong Kong

Mycophenolate mofetil (MMF) has been increasingly used in patients with systemic lupus erythematosus (SLE). While most information concentrates on lupus nephritis, its efficacy in nonrenal manifestations of SLE has not been systematically studied. We describe the successful use of MMF in a patient with SLE-related hemolytic anemia that was refractory to cyclophosphamide, pulse methylprednisolone, intravenous immunoglobulin and cyclosporine. The mechanisms of action of MMF are briefly reviewed.

Key Words: haemolysis • haematological • mycophenolic acid • immunosuppressive • transplant

Lupus, Vol. 14, No. 10, 856-858 (2005)
DOI: 10.1191/0961203305lu2163cr
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
A. Mak, A. A. C. Cheak, J. Y. S. Tan, H. C. Su, R. C. M. Ho, and C. S. Lau
Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression
Rheumatology, June 3, 2009; (2009) kep120v1.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
J. Posalski, M. Ishimori, D. Wallace, and M. Weisman
Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years
Lupus, May 1, 2009; 18(6): 516 - 521.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Y. Karim, C. N. Pisoni, and M. A. Khamashta
Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not!
Rheumatology, April 1, 2009; 48(4): 332 - 341.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
F Falcini, S Capannini, G Martini, F La Torre, A Vitale, F Mangiantini, F Nacci, M. Cerinic, R Cimaz, and F Zulian
Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study
Lupus, February 1, 2009; 18(2): 139 - 143.
[Abstract] [PDF]

Home page
 LupusHome page
A Sinclair and R Baildon
Mycophenolate mofetil: an overview
Lupus, November 1, 2006; 15(11_suppl): 70 - 77.
[PDF]


Advertisement